Last reviewed 2026-04-20 · How we verify

Col-Probenecid (probenecid)

ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance.

Col-Probenecid, also known as probenecid, is a small molecule drug developed by Merck that targets carbonic anhydrase 9. It is classified as a probenecid drug and was FDA approved in 1951 for indications such as articular gout, chronic gouty arthritis, and hyperuricemia. Probenecid is now off-patent and has multiple generic manufacturers. It has a bioavailability of 99% and a half-life of 5.9 hours. As an off-patent drug, it is widely available in the market.

At a glance

Mechanism of action

ORLYNVAH is a combination drug that includes sulopenem etzadroxil, which fights bacterial infections, and probenecid, which prevents the kidneys from removing sulopenem too quickly. This results in higher levels of sulopenem in the blood, enhancing its effectiveness.

Approved indications

• Uncomplicated UTI

Common side effects

• diarrhea
• nausea
• vulvovaginal mycotic infection
• headache
• vomiting

Drug interactions

• Ketorolac tromethamine
• Ketoprofen
• Indomethacin
• Naproxen
• Methotrexate
• Rifampin
• Lorazepam
• Oral Sulfonylureas
• Valproic Acid
• Sulopenem

Key clinical trials

• Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents (PHASE1)
• Probenecid Administration for Alcohol Craving and Consumption (PHASE2)
• Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI) (PHASE3)
• Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
• Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration (PHASE2)
• The Re-Prosper HF Study (PHASE2,PHASE3)
• Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring (PHASE2)
• Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Col-Probenecid CI brief — competitive landscape report
• Col-Probenecid updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI